Although further research will be needed to elucidate all these questions, the fact that a nanopharmaceutical preparation of systemic Ngb capable of reaching the neurons is already available is an important step in stroke therapy and possibly in the therapy of other neurodegenerative diseases. This evidence concerns the gene NGB and neurodegenerative disease.